Celyad Oncology SA (NASDAQ:CYAD) shares traded 24.74% higher at $2.37 on Wall Street last session.
CYAD stock price is now 162.64% away from the 50-day moving average and 47.64% away from the 200-day moving average. The market capitalization of the company currently stands at $58.08M.
With the price target reduced from $52 to $48, H.C. Wainwright maintained Buy rating for Celyad Oncology SA (NASDAQ: CYAD). On May 25, 2018, Wells Fargo recently initiated its ‘Outperform’ rating on the stock quoting a target price of $44.
There have been several recent changes in the stakes of large investors in CYAD stock. A new stake in Celyad Oncology SA shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $39,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $27,000 in shares of CYAD during the first quarter. In total, there are 10 active investors with 29.13% ownership of the company’s stock.
Celyad Oncology SA (NASDAQ: CYAD) opened at $2.0400 on Wednesday. During the past 12 months, Celyad Oncology SA has had a low of $0.46 and a high of $3.99. The fifty day moving average price for CYAD is $0.9024 and a two-hundred day moving average price translates $1.5737 for the stock.
The latest earnings results from Celyad Oncology SA (NASDAQ: CYAD) was released for Jun, 2022.
Celyad Oncology SA(CYAD) Company Profile
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company’s preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.